Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare
NEW YORK (GenomeWeb) – Hong Kong-based venture capital group ORI Healthcare Fund announced today that it has made an $18 million investment in Boston-based cancer molecular diagnostics startup Pillar Biosciences.
According to ORI, Pillar is advancing a patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which offer high sensitivity and specificity, as well as a fast and affordable method for targeted NGS oncology testing.
The startup has released beta versions of two targeted sequencing panels, one covering somatic mutations associated with lung and colon cancers, and another for BRCA1 and BRCA2 germline mutations. Additional information about beta users of these panels and their content and methodology were not disclosed.
The investment will help Pillar continue its R&D efforts in tissue-based sequencing panels, as well as support efforts to develop new liquid biopsy products, the firm said.
Source: https://www.genomeweb.com/molecular-diagnostics/cancer-dx-firm-pillar-biosciences-gets-18m-investment-ori-healthcare#.Y8jx8nZByUn
Related Posts
Chinese Researchers Achieve Breakthrough in Deep UV Laser Technology (March 26, 2025)
Scientists at the Chinese Academy of Sciences developed a compact solid-state laser system generating a 193 nm coherent vortex beam with improved coherence and reduced power consumption. Using a homemade Yb:YAG crystal amplifier, the system outputs 1030 nm laser light, which is frequency converted through cascaded LBO crystals to produce 193 nm laser with 70 [&
Seizing Entrepreneurial Opportunities in Pudong: Embracing the Rise of Returnee Entrepreneurs
From November 9th to 11th, under the guidance of the United Front Work Department of the Shanghai Municipal Committee (Overseas Chinese Affairs Office of the Municipal Government), the “Overseas Chinese Innovation and Entrepreneurship Study Camp” (the 3rd Study Camp for Overseas Chinese Young Science and Technology Entrepreneurs and the 16th Study C
Based on the SIPS model ChangYi proposes marketing strategies for big health brands
According to the “Gen Z Nutrition Consumption Trend Report,” consumers aged 18-35 account for 83.7% of the total health and wellness market, becoming the main force driving growth. Driven by the “Healthy China” initiative and shifting health awareness, the industry is rapidly developing amid fierce competition. Marketing focus has shifte
Pillar Biosciences Raises $34.5 Million to Accelerate Precision Medicine Innovation
In May 2025, Pillar Biosciences announced it had raised $34.5 million in funding, with participation from Illumina, Soleus Capital, and existing investors. The proceeds will be used to expand commercial activities, strengthen partnerships with biopharma companies, and accelerate the adoption of its distributable clinical testing kits worldwide. Pillar’s SLIMa
Leave a Reply